Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules.
OBJECTIVE
To examine the effects of treatment of antigen-induced arthritis in rabbits with a monoclonal antibody against CD18, the common beta chain of the leukocyte adhesion molecules. Intraarticular injection of antigen into primed rabbits elicits an acute inflammatory response followed by chronic arthritis in this model.


METHODS
Anti-CD18 was given at the time of intraarticular antigen administration, and effects on the acute and chronic arthritis were investigated. Twenty-four rabbits were examined (11 controls, 3 receiving normal mouse IgG, and 10 receiving anti-CD18).


RESULTS
Flow cytometry of blood leukocytes at anti-CD18 administration showed saturating amounts of mouse Ig coating all the circulating cells. Treatment effects on the acute arthritis (measured by quantitating the synovial cell exudate 24 hours after arthritis induction) were a profound reduction in the number of inflammatory cells and a striking decrease in the proportion of polymorphonuclear leukocytes recovered from the synovial cavity, indicating a decrease in acute inflammation. Treatment effects on the chronic synovitis (2 and 4 weeks later) compared with controls showed a significant decrease in synovial fluid cell counts at 2 weeks (1.7 versus 21.0 x 10(6)/joint, P less than 0.03) and at 4 weeks (7.4 versus 22.6 x 10(6)/joint, P less than 0.05). Histologic evaluation of the synovium (0-3+ scale, scored "blindly") of anti-CD18-treated rabbits and controls showed marked decreases in subsynovial cell infiltration and lymphoid follicle formation both at 2 weeks (1.0 versus 2.25, P less than 0.005; and 0 versus 1.75, P less than 0.001) and at 4 weeks (1.48 versus 2.17, P less than 0.01; and 0.75 versus 2.08, P less than 0.02). Quantitation of cartilage-bound immune complexes, and of synovial synthesis of Ig and specific antibody showed no differences between groups.


CONCLUSIONS
These findings indicate that treatment with monoclonal antibody to CD18 not only modifies the initial acute arthritis, but also results in significant amelioration of the subsequent chronic inflammation in this animal model of rheumatoid arthritis.
Jasin
H E
HE
Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas.
Lightfoot
E
E
Davis
L S
LS
Rothlein
R
R
Faanes
R B
RB
Lipsky
P E
PE
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000921:Antibody-Producing Cells / Q000166:cytology; D000936:Antigen-Antibody Complex / Q000032:analysis; D000941:Antigens / Q000008:administration & dosage*; D015703:Antigens, CD / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000209:etiology* / Q000276:immunology / Q000628:therapy; D018821:CD18 Antigens; D015815:Cell Adhesion Molecules / Q000276:immunology*; D007596:Joints / Q000276:immunology; D007700:Kinetics; D019041:L-Selectin; D011817:Rabbits; D013583:Synovial Membrane / Q000166:cytology / Q000473:pathology
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D000941:Antigens; D015703:Antigens, CD; D018821:CD18 Antigens; D015815:Cell Adhesion Molecules; D019041:L-Selectin